Hob Biotech: MM09 sublingual spray Phase III clinical trial completes enrollment of the first batch of subjects
Hob Biotech has signed an exclusive strategic cooperation agreement with Inmunotek to introduce the Oraltek® series of desensitization drugs into the Chinese market. The company's wholly-owned subsidiary, Shanghai Hob Biotech, has successfully completed the enrollment of the first batch of subjects for the Phase III clinical trial of the MM09 sublingual spray. In addition, three desensitization drugs have obtained clinical urgent import approval in the Guangdong-Hong Kong-Macao Greater Bay Area
According to the Zhitong Finance APP, Hob Biotech (688656.SH) announced that the company has signed an exclusive strategic cooperation agreement with Inmunotek, under which the company will exclusively introduce Inmunotek's Oraltek® series of desensitization drugs to the Chinese market, carry out domestic sales and registration of the Oraltek series desensitization drugs, and implement the company's new business in the domestic desensitization drug field. This will help connect the upstream and downstream businesses in the allergy industry and address the issues caused by the lack of relevant drugs that severely impact the development of the allergy diagnosis and treatment industry, as well as restrict the development of allergy testing services, thereby meeting the treatment needs of allergy patients.
Recently, the company received a notification from its wholly-owned subsidiary Shanghai Hob Biotech Co., Ltd. (referred to as "Shanghai Hob Biotech") that the Phase III clinical trial for the desensitization drug MM09 sublingual spray, jointly applied for by Shanghai Hob Biotech and Inmunotek, has successfully completed the enrollment and administration of the first batch of subjects. In addition, relying on the support of the "Hong Kong-Macao Drug and Medical Device Access" policy from the Guangdong Provincial Drug Administration, three single products for cat hair, dog hair, and house dust mites/dust mites have successfully obtained the "Mainland Clinical Urgently Needed Import Drug Approval for the Guangdong-Hong Kong-Macao Greater Bay Area."
